12:00 PM EST

Join us for an overview of HARMONIA, a Phase 3 study designed to assess the efficacy and safety of zeleciment basivarsen, an investigational medicine, in individuals living with myotonic dystrophy type 1 (DM1). The discussion will cover the design of the investigational FORCE^TM platform intended to enable targeted tissue delivery, and an overview of the HARMONIA study including study design, eligibility criteria, the scientific rationale for selecting the 5xSTS as the primary endpoint and the study's secondary and exploratory endpoints spanning multiple organ systems, including the CNS.